BeOne Medicines AG

BeOne Medicines reported second-quarter 2026 total revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS of $2.05, up 144%. BRUKINSA global revenue exceeded $1.2 billion, up 31%, while TEVIMBRA sales rose 18% to $229 million. The company raised its 2026 revenue guidance by $300 million to a range of $6.6 billion to $6.8 billion and lifted its GAAP operating income guidance by $250 million to $1.0 billion to $1.1 billion. Free cash flow doubled to $435 million, and adjusted diluted EPS was $3.84 versus $2.25 a year ago. The Phase 3 MANGROVE study showed BRUKINSA plus rituximab as the first chemo-free regimen for frontline mantle cell lymphoma with a hazard ratio of 0.57 versus standard of care.

BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a collaboration in early August 2026 that includes BeOne funding a global Phase 3 trial for Revolution Medicines' RAS(ON) inhibitors. The deal combines BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights in select Asian markets. This arrangement offloads near-term late-stage costs for Revolution Medicines, which reported a net loss of US$644.37 million for the second quarter of 2026 and US$1,098.19 million over six months. The core catalyst remains regulatory progress and eventual commercialization of daraxonrasib, with ongoing large-scale trial execution and spending still posing significant risk.

BeOne Medicines announced a $300 million expansion of its flagship manufacturing and R&D center in Hopewell, New Jersey, bringing its total U.S. manufacturing investment to more than $1 billion. The expansion will add small molecule manufacturing capacity alongside existing biologics production, creating a fully integrated, multi-platform manufacturing site. The new three-story, 145,000-square-foot building will house drug product manufacturing, packaging operations, quality control labs, and office space, increasing the total campus footprint to approximately 545,000 square feet. BeOne expects the project to generate about 120 new full-time jobs, strengthening domestic production capabilities and supporting its oncology pipeline of more than 35 clinical and commercial-stage assets. Chief Financial Officer Aaron Rosenberg emphasized that the investment reflects BeOne's commitment to expanding access to innovative cancer medicines while benefiting from supportive federal tax policies and state manufacturing programs.

RBC Capital analyst Leonid Timashev raised the price target on BeOne Medicines AG to $436 from $425 while maintaining an Outperform rating, following the company's ASCO presentations featuring three oncology programs. The programs include a CDK4 inhibitor for breast cancer, a GPC3-41BB bispecific candidate for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer. RBC Capital noted that these assets demonstrated encouraging potential, with differentiated safety or efficacy profiles that could position them as leading therapies or strong competitors in their respective markets over time. More recently, on June 11, BeOne Medicines presented Phase 3 data from the SEQUOIA trial in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma, showing sustained clinical benefits with Brukinsa after nearly 6.5 years of follow-up. The findings further supported Brukinsa's strong efficacy and safety profile, reinforcing its potential position as a foundational therapy in CLL.

BeOne Medicines announced positive topline results from the Phase 3 MANGROVE study, showing that its BTK inhibitor BRUKINSA plus rituximab reduced the risk of progression or death by 43% compared to bendamustine plus rituximab in adults with previously untreated mantle cell lymphoma. The trial met its primary endpoint of progression-free survival with a hazard ratio of 0.57 and a p-value less than 0.0001. MANGROVE is the first Phase 3 trial to evaluate a chemotherapy-free, rituximab maintenance-free regimen in this setting, potentially sparing patients approximately two years of infusions. The safety profile was consistent with known profiles of both medicines, and overall survival data were immature but showed a strong trend favoring the BRUKINSA combination. Full results will be presented at an upcoming medical meeting, and global regulatory submissions are planned for the second half of 2026.

BeOne Medicines presented new clinical data at the 2026 ASCO Annual Meeting, accelerating progress across three high-priority solid tumor development programs. The CDK4 inhibitor BGB-43395 showed promising efficacy in first-line metastatic breast cancer and will enter a Phase 3 trial this month. The B7-H4 ADC BG-C9074 demonstrated encouraging results in ovarian cancer, while the GPC3x4-1BB bispecific antibody BGB-B2033 exhibited significant anti-tumor activity in heavily pre-treated hepatocellular carcinoma. The company aims to establish new standards of care in breast, gynecologic, and gastrointestinal cancers.

Citizens maintained its Market Outperform rating and $396 price target on BeOne Medicines AG. The firm highlighted robust clinical data for three pipeline drugs presented at the ASCO 2026 conference, including BGB-43395 for HR+/HER2- metastatic breast cancer, BG-C9074 for ovarian cancer maintenance, and BGB-B2033 for liver cancer. Citizens believes each drug targets patient populations where current treatments are too toxic, face resistance, or do not exist, marking an inflection point for the company's tumor strategy. The $396 price target is based on a discounted earnings and revenue multiple analysis, and the firm expressed confidence in BeOne's funding ability given its $4.85 billion in cash, more cash than debt, and 88% gross profit margins.

BeOne Medicines presented updated Phase 3 clinical data for its BTK inhibitor BRUKINSA at the European Hematology Association Congress. The 78-month SEQUOIA study showed a progression-free survival rate of 71.8% with BRUKINSA compared to 31% with bendamustine-rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The safety profile remained consistent with previous studies, reinforcing BRUKINSA's role as a foundational BTK inhibitor after nearly 6.5 years of follow-up. BRUKINSA is currently approved in 80 markets for various B-cell blood cancers.